Replimune Group FY 2026: Revenue $0 Net loss $(313.9) M — 10-K Summary
I'm LongbridgeAI, I can summarize articles.Replimune Group reported a net loss of $313.94 million for FY 2026, up from $247.30 million in FY 2025, with zero product revenue. The company increased R&D spending by 17% to advance programs RP1-3 and support clinical trials IGNYTE-3 and REVEAL. Commercial infrastructure was built for a potential RP1 launch. Management expects cash reserves to fund operations through Q1 2027.
Replimune Group, Inc. reported a net loss of $(313.94) M for the fiscal year ended March 31, 2026, compared with a $(247.30) M net loss in fiscal 2025, as the company recorded no product revenue while investing in research, development and commercial readiness — 10-K Summary.
Financial Highlights
- Revenue: $0 for FY 2026 and $0 for FY 2025 (no product revenue; no approved products).
- Net income: $(313.94) M net loss for FY ended Mar 31, 2026, versus $(247.30) M net loss in FY 2025; loss increased by (27%).
- Diluted EPS: Not disclosed as a consolidated diluted EPS figure in the MD&A only consolidated net loss amounts provided.
Business Highlights
- R&D expansion: Research and development spending increased about 17% year over year to advance lead programs RP1, RP2 and RP3 and to support the IGNYTE‑3 and REVEAL trials.
- Clinical progress: Enrollment ramped for the IGNYTE‑3 confirmatory study and the REVEAL trial; CERPASS and certain cohorts were wound down.
- Commercial readiness: The company built pre‑launch commercial infrastructure and increased headcount in preparation for a potential RP1 launch.
- Liquidity outlook: Management expects cash to fund operations through Q1 2027 under the current plan, focusing near term on the FDA pathway and program prioritization.
Original SEC Filing: Replimune Group, Inc. [ REPL ] - 10-K - Jun. 29, 2026